Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

First in human, dose escalation study of VRN110755 in non-small cell lung cancer patients with EGFR mutations

Next Previous
Trial Profile

First in human, dose escalation study of VRN110755 in non-small cell lung cancer patients with EGFR mutations

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 09 Jun 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs VRN 11 (Primary) ; Afatinib; Dacomitinib; Osimertinib
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions; First in man

Most Recent Events

  • 09 Jun 2025 New trial record
  • 30 Apr 2025 Results assessing safety, pharmacokinetics, and early efficacy of VRN-11 in patients with non-small cell lung cancer patients were presented at the 116th Annual Meeting of the American Association for Cancer Research

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top